

HIPRA appoints Sergi Berthet as Manager Director of the Corporate Area

His appointment strengthens the company's leadership by taking over the Corporate Area, which includes departments with a transversal impact across the entire organization

Girona, 24 July 2025 – HIPRA, a biotechnological pharmaceutical company specializing in the development of vaccines for animal and human health, continues to reinforce its management structure with the appointment of Sergi Berthet Colominas as Manager Director of the Corporate Area.

With an international career spanning over 25 years in the industrial and pharmaceutical sectors, Berthet has held top executive positions at AptarGroup, where he served as Vice-President and General Manager for the Pharma Prescription and EMEA Personal Care/Home Care divisions, as well as CEO of Aptar France. He has also held leadership roles at companies such as Unilever, BIC Graphic Europe and Decathlon, always linked to operations management and business development.

Trained as an industrial engineer at HEI Lille, with a specialization in Macromolecular Chemistry at the University of Science and Technology of Lille (USTL), Berthet completed a thesis in protein crystallography at the Spanish National Research Council (CSIC). This strong technical and scientific background complements his business vision and leadership capabilities in high-level environments.

Sergi Berthet takes on the leadership of the Corporate Area, which encompasses departments with cross-cutting impact throughout the organization, ensuring continuity of the project and reinforcing the company's commitment to a robust structure ready to face future challenges with determination and leadership.

About HIPRA

HIPRA is a biotechnology pharmaceutical company focused on prevention in animal and human health (One Health), with a broad range of highly innovative vaccines and an advanced diagnostic service. Under the motto "Building immunity for a healthier world", HIPRA reaffirms its commitment to delivering solutions that improve global health. It has a strong international presence with 40 subsidiaries, 3 R&D centers, and 6 production sites strategically located in Europe (Spain) and the Americas (Brazil). In

addition, its extensive international distribution network keeps marketing channels open in over 100 countries, thus covering all 5 continents.

Research and development are at the core of its expertise. HIPRA dedicates more than 10% of its annual revenue to R&D activities focused on applying the latest scientific advances to develop innovative, high-quality vaccines. HIPRA's portfolio includes vaccines based on various technological platforms. Its R&D teams work with a wide range of pathogens, some of which are listed by the WHO as potential pandemic threats.

To add further value to its vaccination expertise, the company also develops medical devices and traceability services for animal health.

Press contacts

Irene Calle – icalle@harmon.es – M. 609 873 052

José María Nieto – jnieto@harmon.es – M. 689 186 062